



Genglycos™ Gene Therapy Treatment Centers ETS Program Reference Guide

Emerging Therapy Solutions® (ETS) helps reinsurance and stop-loss payers, health plans, HMOs, and self-funded employers, along with third-party administrators and brokers, manage the risk associated with high-cost therapies for rare and complex conditions. Programs listed here are qualified treatment centers (QTCs) for which ETS either may have contracted rates in place or may have access to rates through single case agreements for **Genglycos™** (pariglasgene breCAParvovec-opnr) which is approved to treat **glycogen storage disease type Ia**.

For assistance with your member referral or for more information, contact ETS at 877-445-4822 or by email at clientservices@emergingtherapies.com.

▼ Denotes facilities at which ETS has gene therapy rates in place.

State	City	Program Listing
Arkansas	Little Rock	Arkansas Children's Hospital
California	Los Angeles	U.C.L.A. Medical Center
Illinois	Chicago	Ann & Robert H. Lurie Children's Hospital of Chicago
Missouri	St. Louis	St. Louis Children's Hospital ▼
Ohio	Columbus	Nationwide Children's Hospital
Wisconsin	Milwaukee	Children's Hospital of Wisconsin